MX2019003258A - Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana. - Google Patents

Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana.

Info

Publication number
MX2019003258A
MX2019003258A MX2019003258A MX2019003258A MX2019003258A MX 2019003258 A MX2019003258 A MX 2019003258A MX 2019003258 A MX2019003258 A MX 2019003258A MX 2019003258 A MX2019003258 A MX 2019003258A MX 2019003258 A MX2019003258 A MX 2019003258A
Authority
MX
Mexico
Prior art keywords
inmunogenic
synthetic consensus
activation protein
fibroblast activation
optimized synthetic
Prior art date
Application number
MX2019003258A
Other languages
English (en)
Inventor
Weiner David
Duperret Elizabeth
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Publication of MX2019003258A publication Critical patent/MX2019003258A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Abstract

En la presente se proporciona una composición inmunogénica que comprende un antígeno FAP de consenso sintético; también se divulga en la presente un método para tratar o prevenir una patología asociada con un tumor en un sujeto que lo necesite, administrando la composición inmunogénica al sujeto.
MX2019003258A 2016-09-21 2017-09-21 Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana. MX2019003258A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662397469P 2016-09-21 2016-09-21
PCT/US2017/052701 WO2018057727A1 (en) 2016-09-21 2017-09-21 Optimized synthetic consensus inmunogenic compositions targeting fibroblast activation protein

Publications (1)

Publication Number Publication Date
MX2019003258A true MX2019003258A (es) 2019-09-13

Family

ID=61690028

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003258A MX2019003258A (es) 2016-09-21 2017-09-21 Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana.

Country Status (10)

Country Link
EP (1) EP3515466A4 (es)
JP (1) JP2019532935A (es)
KR (1) KR20190092371A (es)
CN (1) CN110167576A (es)
AU (1) AU2017330338A1 (es)
BR (1) BR112019005513A2 (es)
CA (1) CA3037682A1 (es)
EA (1) EA201990768A1 (es)
MX (1) MX2019003258A (es)
WO (1) WO2018057727A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230167445A (ko) * 2016-09-30 2023-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Tert 면역원성 조성물 및 이를 이용한 치료 방법
CN111118063B (zh) * 2019-12-05 2023-04-18 吉林大学 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用
CN112402597B (zh) * 2020-11-26 2022-04-01 四川大学 一种fap修饰的类外泌体纳米囊泡肿瘤疫苗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472375B1 (en) * 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
WO2007149518A2 (en) * 2006-06-21 2007-12-27 The Scripps Research Institute Dna composition against tumor stromal antigen fap and methods of use thereof
JP5764127B2 (ja) * 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
US9303079B2 (en) * 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9402888B2 (en) * 2013-03-14 2016-08-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
KR20230167445A (ko) * 2016-09-30 2023-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Tert 면역원성 조성물 및 이를 이용한 치료 방법

Also Published As

Publication number Publication date
WO2018057727A1 (en) 2018-03-29
KR20190092371A (ko) 2019-08-07
CA3037682A1 (en) 2018-03-29
BR112019005513A2 (pt) 2019-06-11
EA201990768A1 (ru) 2019-08-30
JP2019532935A (ja) 2019-11-14
EP3515466A4 (en) 2020-05-27
AU2017330338A1 (en) 2019-05-02
CN110167576A (zh) 2019-08-23
EP3515466A1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
MX2022007522A (es) Anticuerpos anti-cd27.
EA201991214A1 (ru) Антитела против pd-1 и их композиции
EA201800148A1 (ru) Оспенная вакцина для лечения рака
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
PH12018500578A1 (en) Methods of treating inflammatory diseases
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
MX2017007187A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2017006464A (es) Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
MX2019003258A (es) Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2019014291A (es) Metodo de tratamiento.
MX2018014716A (es) Anticuerpos anti-tnfrsf25.
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
MX2021015922A (es) Proteínas quiméricas sintéticas estabilizadas y sus usos terapéuticos.
EA201892675A1 (ru) Фармацевтическая композиция, содержащая этеплирсен
MY173606A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease